US20060099151A1 - Stable foam cream - Google Patents
Stable foam cream Download PDFInfo
- Publication number
- US20060099151A1 US20060099151A1 US10/538,666 US53866603A US2006099151A1 US 20060099151 A1 US20060099151 A1 US 20060099151A1 US 53866603 A US53866603 A US 53866603A US 2006099151 A1 US2006099151 A1 US 2006099151A1
- Authority
- US
- United States
- Prior art keywords
- percent
- weight
- foam cream
- cream
- foam
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000006260 foam Substances 0.000 title claims abstract description 113
- 239000006071 cream Substances 0.000 title claims abstract description 99
- 238000010438 heat treatment Methods 0.000 claims abstract description 42
- 239000003380 propellant Substances 0.000 claims abstract description 27
- 238000004519 manufacturing process Methods 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims description 32
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 18
- -1 poly(ethylene glycol) Polymers 0.000 claims description 17
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 239000000194 fatty acid Substances 0.000 claims description 10
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 claims description 9
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 8
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 8
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 8
- 229930195729 fatty acid Natural products 0.000 claims description 8
- 150000004665 fatty acids Chemical class 0.000 claims description 7
- 235000011187 glycerol Nutrition 0.000 claims description 7
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 239000000654 additive Substances 0.000 claims description 6
- 239000003995 emulsifying agent Substances 0.000 claims description 6
- 235000002961 Aloe barbadensis Nutrition 0.000 claims description 5
- 244000186892 Aloe vera Species 0.000 claims description 5
- 235000011399 aloe vera Nutrition 0.000 claims description 5
- 229940101267 panthenol Drugs 0.000 claims description 5
- 235000020957 pantothenol Nutrition 0.000 claims description 5
- 239000011619 pantothenol Substances 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 4
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 4
- 241000723346 Cinnamomum camphora Species 0.000 claims description 4
- 229910019142 PO4 Inorganic materials 0.000 claims description 4
- 244000305267 Quercus macrolepis Species 0.000 claims description 4
- 244000178231 Rosmarinus officinalis Species 0.000 claims description 4
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 4
- 229960000458 allantoin Drugs 0.000 claims description 4
- 229960000846 camphor Drugs 0.000 claims description 4
- 229930008380 camphor Natural products 0.000 claims description 4
- 239000004202 carbamide Substances 0.000 claims description 4
- 229940081733 cetearyl alcohol Drugs 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 4
- 229940075529 glyceryl stearate Drugs 0.000 claims description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 4
- 239000012188 paraffin wax Substances 0.000 claims description 4
- 239000010452 phosphate Substances 0.000 claims description 4
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 4
- 235000002020 sage Nutrition 0.000 claims description 4
- 229960004418 trolamine Drugs 0.000 claims description 4
- ZFCFLWMYLATFES-UHFFFAOYSA-N 2-[hexadecyl(methyl)amino]acetic acid Chemical compound CCCCCCCCCCCCCCCCN(C)CC(O)=O ZFCFLWMYLATFES-UHFFFAOYSA-N 0.000 claims description 3
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- 235000004866 D-panthenol Nutrition 0.000 claims description 3
- 239000011703 D-panthenol Substances 0.000 claims description 3
- 235000021355 Stearic acid Nutrition 0.000 claims description 3
- 239000007957 coemulsifier Substances 0.000 claims description 3
- 229960003949 dexpanthenol Drugs 0.000 claims description 3
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims description 3
- 230000000887 hydrating effect Effects 0.000 claims description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 239000001540 sodium lactate Substances 0.000 claims description 3
- 229940005581 sodium lactate Drugs 0.000 claims description 3
- 235000011088 sodium lactate Nutrition 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 239000008117 stearic acid Substances 0.000 claims description 3
- 241000208983 Arnica Species 0.000 claims 2
- 239000007789 gas Substances 0.000 description 20
- 239000000203 mixture Substances 0.000 description 11
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 8
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 4
- 239000001294 propane Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000001273 butane Substances 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- 239000001282 iso-butane Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 239000002884 skin cream Substances 0.000 description 2
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- 241000086254 Arnica montana Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 150000002763 monocarboxylic acids Chemical class 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000008149 soap solution Substances 0.000 description 1
- 229940045885 sodium lauroyl sarcosinate Drugs 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/046—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/122—Foams; Dry foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Definitions
- the invention relates to a stable foam cream, containing lipophilic and hydrophilic components and a propellant gas, obtainable by subjecting the foam cream to a heat treatment, as well as to methods for the manufacture of a stable foam cream.
- foam preparations are utilized, inter alia, as skin creams.
- the foam is formed by foaming a basic preparation with a propellant gas.
- a two-dimensional two-phase network is formed on the treated skin, the hydrophilic components bind to the keratin of the horn layer and allow for an evaporation of sweat, while the lipophilic parts inhibit the penetration of moisture at the skin surface.
- foam creams are, inter alia, described in documents WO-A99/08649 and WO-A-98/31339.
- foams in the form of aerosols are complex physico-chemical forms which cannot be manufactured at will.
- the stability of such foams is strongly dependent on the specific composition of the foam forming components. Even small deviations in the composition may lead to a collapse of the foam. “Collapsing” means that the foam, directly after its release from the tin, shows a strong formation of blisters and then collapses. This interferes with the positive properties of the foam (particularly its rapid absorption after application to the skin) and is consequently not accepted by the consumers. Therefore, a mixture of active agents per se cannot be formulated as a foam without any further ado. It is often observed that a normally stable foam tends to collapse upon addition of a further component.
- WO 99/08649 discloses a technique, in which two separated phases I and II are provided in an exact protocol, pre-treated and mixed. The method comprises several steps which have to be carefully controlled by the manufacturer.
- GB-A-2 204 875 relates to a method for realizing monocarboxylic acids. Finely divided particles are contacted with C 10 -C 22 carboxylic acids in an aqueous medium with a neutralizing agent, for example ethanolamine, at a temperature below the melting point of said fatty acids. This results in pumpable liquid soap solutions containing 0.3 percent by weight to 40 percent by weight of soap. These are used for the manufacture of shaving foams by admixing C 3 -or C 4 -hydrocarbon propellant gases.
- a neutralizing agent for example ethanolamine
- FR-A-2,217,405 relates to the preparation of foam creams in the form of oil-in-water emulsions.
- WO-A-98/31339 relates to skin care products made by a two-phase system which is capable of producing a semi-permeable membrane on the skin.
- a stable foam cream containing lipophilic and hydrophilic components and a propellant gas obtainable by subjecting the foam cream to a heat treatment, characterized in that the treatment is conducted over a time period of at least 5, preferably 10 minutes, and/or 4 minutes to two hours at 40 to 75° C.
- the heat treatment is done after the addition of the propellant gas.
- the heat treatment is done by heating the propellant gas before and/or during its addition to the cream preparation. Both methods may be combined according to the invention.
- the heat treatment after the addition of the propellant gas has to be done dependent on time and temperature. Generally there is a reciprocal relationship between the temperature of the heat treatment and the duration thereof. If the heat treatment is done at a relatively high temperature, a relatively short treatment period is sufficient, and vice versa.
- the heat treatment should be conducted for at least about 10 minutes, 30 minutes or 1 hour.
- the temperature is at least 30° C., at least 40° C. or at least 50° C. It should not fall below 20° C. in order to avoid too long treatment periods.
- the treatments may be carried out at 40 to 70° C., particularly at 45 to 65° C. for 5 minutes to 2 hours, at 40 to 60° C. for 10 minutes to 5 hours, or at 30 to 50° C. for 20 minutes to 20 hours, particularly 1 hour to 15 hours.
- An industrially practical heat treatment may involve, for example, a period of 20 minutes at 50° C., 10 hours at 50° C. or 12 hours at 38° C.
- the heat treatment should be carried out for long periods (in an hourly range) at no more than about 50° C.
- the heat treatment is preferably done by incubation, for example in a heating cabinet, a heating chamber or an incubation room.
- the heat treatment is particularly carried out after addition of the propellant gas.
- the heat treatment of the tins containing the foam cream may be carried out on pallets in heating chambers. Temperatures of 35-40° C. for a period of 10 to 40 hours can be used.
- the foam cream can be first dosed or bottled and then subjected to the heat treatment.
- a further possibility for producing a stable foam cream is the heating of the propellant gas before or during its addition to the hydrophilic and lipophilic components. This is in contrast to well known methods, wherein the propellant gas is feeded with cooling.
- the heating of the propellant gas is preferably done at 25 to 60° C., particularly 25 to 50° C. or 25 to 40° C. It may be advantageous to heat the propellant gas to at least 30° C. or 40° C.
- a pressure test of the bottled tins comprising the propellant gas may be used as a (partial) heat treatment according to the present invention.
- the tins are conducted through a water bath heated to 40 to 50° C. The relevant residence times in the water bath can be deducted from the incubation time.
- the inventive stable foam cream is a two-phase system.
- the lipophilic components comprise fatty acids and dimethyl polysiloxanes, and the hydrophilic components are selected from the group consisting of triethanol-amine, mono propylene glycol, glycerine, sorbitol, poly(ethylene glycol) and poly(vinyl pyrrolidone).
- the inventive foam cream comprises C 10 - to C 22 -fatty acids, emulsifiers and co-emulsifiers.
- the inventive foam cream comprises
- the inventive foam cream may additionally comprise
- the stable foam cream may, as additional components, further comprise hydrating (moisture binding) substances like urea, ethoxy diglycol, sodium chloride, magnesium chloride, sorbit, dexpanthenol, sodium lactate.
- hydrating moisture binding substances like urea, ethoxy diglycol, sodium chloride, magnesium chloride, sorbit, dexpanthenol, sodium lactate.
- Further preferred additives of the stable foam cream are clotrimazol, oak bark extract, sage, rosemary, amica, aloe vera, panthenol and camphor. These additives significantly destabilise foam creams.
- the inventive stable foam cream provides improved properties after the heat treatment, when compared to foam creams known in the prior art.
- the described phenomenon of collapsing of the foams substantially does not occur.
- the foam creams are stable over a long period of time, and are substantially resistant against exterior disturbing actions like shaking during transport or temperature fluctuations.
- the inventive foam cream is stable even if it contains substances which destabilize foam creams not treated in accordance with the present invention.
- the inventive stable foam cream is, in a preferred embodiment, a cosmetic or medicinal foam cream, particularly a skin foam cream. It may contain commonly known components and additives for such skin creams, like those disclosed, for example, in WO-A-98/3 1339 or WO-A-99/08649.
- the present invention also relates to a method of manufacture of a stable foam cream, comprising lipophilic and hydrophilic components and a propellant gas, which is characterized in that in this method a cream preparation comprising lipophilic and hydrophilic components is prepared, then propellant gas is added, so that a foam cream is formed, and the foam cream is subjected to a heat treatment and/or the propellant gas is heated before and/or during its addition to the cream preparation.
- the propellant gas is heated before and/or during its addition to the cream preparation.
- the foam cream has collapsed or partially collapsed after addition of the propellant gas and before carrying out the heat treatment.
- the inventive method does not only allow for a stabilization of foam creams, but also allows to reconstitute foam creams which have collapsed after addition of the propellant gas and typically can no longer be used by the manufacturer, by carrying out a heat treatment.
- the foam cream is prepared in a closed apparatus which can be heated and cooled and which is equipped with a self-discharging homogenizer and a heatable dosing funnel.
- the manufacture of phase I is done in a heatable dosing funnel by melting a mixture comprising 2 weight percent of glyceryl stearate, 4 weight percent of cetearyl alcohol, 5 weight percent of stearyl acid, 1 weight percent of paraffin, 0.5 weight percent of triceteareth-4-phosphate, 5 weight percent of decyl oleate, 5 weight percent of octyl dodecanol and 0.2 weight percent of dimethicone at 75° C.
- This phase is metered under stirring to a phase II already present in a closed apparatus which can be heated and cooled and which comprises a self-discharging homogenizer.
- This phase II consists of an aqueous mixture comprising 5.5 weight percent of urea, 2.5 weight percent propylene glycol, 2.5 weight percent of glycerine, 2 weight percent of sodium lauroyl sarcosinate and 63 weight percent of water. Formation of a homogenous blend of both phases I and II has to be assured.
- phase I The metered addition of phase I is done at a temperature of 75° C. Both phases are combined while permanently stirring at a medium stirring speed, and a uniform homogenizing has to be assured. The temperature is held between 20 and 30 minutes at 75° C. Thereafter, 0.1 weight percent allantoin and 1.1 weight percent of triethanolamine (for adjusting the pH-value to a value between 7.8 and 8.0) are added. The resulting mixture is cooled to a temperature of from 30 to 40° C. while stirring permanently.
- the manufacture of a foam cream is carried out according to the method of Example 1.
- the propane/butane-mixture may be warmed to 25° C. before adding.
- the preparation of a foam cream is carried out in accordance with the method as described in Example 1. After filling of the foam cream, the filled containers are heated for 20 minutes in a heating cabinet with an interior temperature of 50° C.
- the preparation of a foam cream is carried out in accordance with the method as described in Example 1, wherein the propane/butane-mixture to be added may be warmed to 25° C. and the filled containers are stored after filling of the foam cream for 12 hours in a storage room at 38° C.
- a foam cream is prepared in accordance with Example 1, with the difference that instead of aloe vera and panthenol, clotrimazol is added to the mixture. The rest of the procedure is as described in Example 1. The addition of this component destabilizes foam creams to a large extent and typically results in a collapse of the foam cream.
- One part of the foam cream is subjected to a heat treatment in accordance with Example 2, another part is subjected to a heat treatment in accordance with Example 4.
- Example 6 The same procedure as described in Example 6 is carried out, with the difference that instead of adding clotrimazol to the foam cream, oak bark extract is added. This additive can destabilize foam creams and typically leads to a collapse of the foam cream.
- Example 6 The procedure as described in Example 6 is carried out, with the difference that instead of clotrimazol, sage is added to the foam cream.
- sage is added to the foam cream.
- the addition of this component destabilizes foam creams to a large extent and typically leads to a collapse of the foam cream.
- Example 6 The procedure as described in Example 6 is carried out, with the difference that instead of clotrimazol, rosemary is added to the foam cream.
- rosemary is added to the foam cream.
- the addition of this component destabilizes foam creams to a large extent and typically leads to a collapse of the foam cream.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Birds (AREA)
- Dispersion Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
- Grain Derivatives (AREA)
Abstract
The invention relates to a stable foam cream, containing lipophilic and hydrophilic components and a propellant gas, obtainable by subjecting the foam cream to heat treatment. The invention also relates to the production thereof.
Description
- The invention relates to a stable foam cream, containing lipophilic and hydrophilic components and a propellant gas, obtainable by subjecting the foam cream to a heat treatment, as well as to methods for the manufacture of a stable foam cream.
- The principle for preparing an emulsoid two-phase system comprising lipophilic or hydrophobic parts, respectively, on the one hand, and hydrophilic components on the other hand, for the manufacture of foam preparations is well known. Such foam preparations are utilized, inter alia, as skin creams. The foam is formed by foaming a basic preparation with a propellant gas. When using such foam preparations, a two-dimensional two-phase network is formed on the treated skin, the hydrophilic components bind to the keratin of the horn layer and allow for an evaporation of sweat, while the lipophilic parts inhibit the penetration of moisture at the skin surface. Such foam creams are, inter alia, described in documents WO-A99/08649 and WO-A-98/31339.
- However, such foams in the form of aerosols are complex physico-chemical forms which cannot be manufactured at will. The stability of such foams is strongly dependent on the specific composition of the foam forming components. Even small deviations in the composition may lead to a collapse of the foam. “Collapsing” means that the foam, directly after its release from the tin, shows a strong formation of blisters and then collapses. This interferes with the positive properties of the foam (particularly its rapid absorption after application to the skin) and is consequently not accepted by the consumers. Therefore, a mixture of active agents per se cannot be formulated as a foam without any further ado. It is often observed that a normally stable foam tends to collapse upon addition of a further component. The manufacturer of such foams are generally well aware of the problem that upon manufacturing of well-tested stable foams, one batch is unexpectedly produced in which the foam collapses. Then, this batch has to be newly produced. If the problem is not already recognized by the manufacturer, the result is an unsatisfactory use by the customer. Collapsed or broken down foams cannot normally be recycled by the manufacturer and have to be disposed.
- According to the prior art, this problem is solved in that specific manufacturing methods are utilized. WO 99/08649 discloses a technique, in which two separated phases I and II are provided in an exact protocol, pre-treated and mixed. The method comprises several steps which have to be carefully controlled by the manufacturer.
- GB-A-2 204 875 relates to a method for realizing monocarboxylic acids. Finely divided particles are contacted with C10-C22 carboxylic acids in an aqueous medium with a neutralizing agent, for example ethanolamine, at a temperature below the melting point of said fatty acids. This results in pumpable liquid soap solutions containing 0.3 percent by weight to 40 percent by weight of soap. These are used for the manufacture of shaving foams by admixing C3-or C4-hydrocarbon propellant gases.
- FR-A-2,217,405 relates to the preparation of foam creams in the form of oil-in-water emulsions.
- WO-A-98/31339 relates to skin care products made by a two-phase system which is capable of producing a semi-permeable membrane on the skin.
- It is an object of the invention to provide foams, which substantially do not collapse and which do not show the above-mentioned problems. Furthermore, methods should be provided to produce such foams and for making collapsed foams reusable.
- Surprisingly, the problem underlying the invention is solved by a stable foam cream containing lipophilic and hydrophilic components and a propellant gas, obtainable by subjecting the foam cream to a heat treatment, characterized in that the treatment is conducted over a time period of at least 5, preferably 10 minutes, and/or 4 minutes to two hours at 40 to 75° C. In particular, the heat treatment is done after the addition of the propellant gas. Alternatively, the heat treatment is done by heating the propellant gas before and/or during its addition to the cream preparation. Both methods may be combined according to the invention.
- The heat treatment after the addition of the propellant gas has to be done dependent on time and temperature. Generally there is a reciprocal relationship between the temperature of the heat treatment and the duration thereof. If the heat treatment is done at a relatively high temperature, a relatively short treatment period is sufficient, and vice versa. The heat treatment should be conducted for at least about 10 minutes, 30 minutes or 1 hour. For example, the temperature is at least 30° C., at least 40° C. or at least 50° C. It should not fall below 20° C. in order to avoid too long treatment periods. The treatments may be carried out at 40 to 70° C., particularly at 45 to 65° C. for 5 minutes to 2 hours, at 40 to 60° C. for 10 minutes to 5 hours, or at 30 to 50° C. for 20 minutes to 20 hours, particularly 1 hour to 15 hours.
- An industrially practical heat treatment may involve, for example, a period of 20 minutes at 50° C., 10 hours at 50° C. or 12 hours at 38° C.
- Naturally, it should be considered during the heat treatment that, dependent on the propellant gas used, there is an upper limit for the heating, which should not be exceeded for safety reasons. When using a mixture of isobutane/butane/propane, the heat treatment should be carried out for long periods (in an hourly range) at no more than about 50° C.
- The heat treatment is preferably done by incubation, for example in a heating cabinet, a heating chamber or an incubation room. The heat treatment is particularly carried out after addition of the propellant gas. According to the invention, it is possible to subject the whole batch to a heat treatment before packaging and mass production. With larger batches, the heat treatment of the tins containing the foam cream may be carried out on pallets in heating chambers. Temperatures of 35-40° C. for a period of 10 to 40 hours can be used. Alternatively, the foam cream can be first dosed or bottled and then subjected to the heat treatment.
- A further possibility for producing a stable foam cream is the heating of the propellant gas before or during its addition to the hydrophilic and lipophilic components. This is in contrast to well known methods, wherein the propellant gas is feeded with cooling. The heating of the propellant gas is preferably done at 25 to 60° C., particularly 25 to 50° C. or 25 to 40° C. It may be advantageous to heat the propellant gas to at least 30° C. or 40° C.
- Also, a pressure test of the bottled tins comprising the propellant gas may be used as a (partial) heat treatment according to the present invention. In such instances, the tins are conducted through a water bath heated to 40 to 50° C. The relevant residence times in the water bath can be deducted from the incubation time.
- Preferably, the inventive stable foam cream is a two-phase system. In preferred embodiments, the lipophilic components comprise fatty acids and dimethyl polysiloxanes, and the hydrophilic components are selected from the group consisting of triethanol-amine, mono propylene glycol, glycerine, sorbitol, poly(ethylene glycol) and poly(vinyl pyrrolidone).
- In a preferred embodiment, the inventive foam cream comprises C10- to C22-fatty acids, emulsifiers and co-emulsifiers.
- In a particularly preferred embodiment, the inventive foam cream comprises
-
- 4 to 15 percent by weight of oil-in-water emulsifier,
- 1 to 10 percent by weight of fatty acid,
- 0.4 to 2.3 percent by weight moisturiser,
- 0.05 to 1 percent by weight skin care agent and
- water balancing to 100 percent by weight.
- The inventive foam cream may additionally comprise
-
- 1 to 3 percent by weight of glyceryl stearate,
- 3 to 6 percent by weight cetearyl alcohol,
- 4 to 6 percent by weight of stearic acid,
- 0.5 to 2 percent of weigth of paraffin,
- 0.4 to 2.3 percent by weight of triceteareth-4-phosphate,
- 1.5 to 4 percent by weight propylene glycol,
- 1.3 to 4.2 percent by weight of glycerine,
- 1 to 3 percent by weight of cetyl-sarcosinate,
- 0.05 to 1 percent by weight of allantoin as
- water balancing to 100 percent by weight.
- The stable foam cream may, as additional components, further comprise hydrating (moisture binding) substances like urea, ethoxy diglycol, sodium chloride, magnesium chloride, sorbit, dexpanthenol, sodium lactate.
- Further preferred additives of the stable foam cream are clotrimazol, oak bark extract, sage, rosemary, amica, aloe vera, panthenol and camphor. These additives significantly destabilise foam creams.
- The inventive stable foam cream provides improved properties after the heat treatment, when compared to foam creams known in the prior art. Thus, the described phenomenon of collapsing of the foams substantially does not occur. Furthermore, the foam creams are stable over a long period of time, and are substantially resistant against exterior disturbing actions like shaking during transport or temperature fluctuations. The inventive foam cream is stable even if it contains substances which destabilize foam creams not treated in accordance with the present invention.
- It is assumed that the foam creams treated in accordance with the invention undergo a structural change, which is responsible for the improved properties.
- The inventive stable foam cream is, in a preferred embodiment, a cosmetic or medicinal foam cream, particularly a skin foam cream. It may contain commonly known components and additives for such skin creams, like those disclosed, for example, in WO-A-98/3 1339 or WO-A-99/08649.
- The present invention also relates to a method of manufacture of a stable foam cream, comprising lipophilic and hydrophilic components and a propellant gas, which is characterized in that in this method a cream preparation comprising lipophilic and hydrophilic components is prepared, then propellant gas is added, so that a foam cream is formed, and the foam cream is subjected to a heat treatment and/or the propellant gas is heated before and/or during its addition to the cream preparation. In a further embodiment, the propellant gas is heated before and/or during its addition to the cream preparation.
- In a preferred embodiment of the inventive method for the manufacture of the stable foam cream, the foam cream has collapsed or partially collapsed after addition of the propellant gas and before carrying out the heat treatment. This means that the inventive method does not only allow for a stabilization of foam creams, but also allows to reconstitute foam creams which have collapsed after addition of the propellant gas and typically can no longer be used by the manufacturer, by carrying out a heat treatment.
- The foam cream is prepared in a closed apparatus which can be heated and cooled and which is equipped with a self-discharging homogenizer and a heatable dosing funnel. The manufacture of phase I is done in a heatable dosing funnel by melting a mixture comprising 2 weight percent of glyceryl stearate, 4 weight percent of cetearyl alcohol, 5 weight percent of stearyl acid, 1 weight percent of paraffin, 0.5 weight percent of triceteareth-4-phosphate, 5 weight percent of decyl oleate, 5 weight percent of octyl dodecanol and 0.2 weight percent of dimethicone at 75° C. This phase is metered under stirring to a phase II already present in a closed apparatus which can be heated and cooled and which comprises a self-discharging homogenizer. This phase II consists of an aqueous mixture comprising 5.5 weight percent of urea, 2.5 weight percent propylene glycol, 2.5 weight percent of glycerine, 2 weight percent of sodium lauroyl sarcosinate and 63 weight percent of water. Formation of a homogenous blend of both phases I and II has to be assured.
- The metered addition of phase I is done at a temperature of 75° C. Both phases are combined while permanently stirring at a medium stirring speed, and a uniform homogenizing has to be assured. The temperature is held between 20 and 30 minutes at 75° C. Thereafter, 0.1 weight percent allantoin and 1.1 weight percent of triethanolamine (for adjusting the pH-value to a value between 7.8 and 8.0) are added. The resulting mixture is cooled to a temperature of from 30 to 40° C. while stirring permanently.
- After a temperature of 40° C. has been reached, 0.5 weight percent of aloe vera and 0.1 weight percent of panthenol are added. The addition of these components significantly destabilizes foam creams and typically leads to a collapse of the foam cream.
- It is stirred for a period sufficiently long enough to stabilize the pH-value and then the foam cream is filled into suitable storage containers or into the pressurized dispenser, respectively, with 9% isobutane/butane/propane.
- After filling of the foam cream of Example 1, heat treatment is carried out in that the filled containers are stored in a storage room at 38° C. for 12 hours.
- The manufacture of a foam cream is carried out according to the method of Example 1. The propane/butane-mixture may be warmed to 25° C. before adding.
- The preparation of a foam cream is carried out in accordance with the method as described in Example 1. After filling of the foam cream, the filled containers are heated for 20 minutes in a heating cabinet with an interior temperature of 50° C.
- The preparation of a foam cream is carried out in accordance with the method as described in Example 1, wherein the propane/butane-mixture to be added may be warmed to 25° C. and the filled containers are stored after filling of the foam cream for 12 hours in a storage room at 38° C.
- A foam cream is prepared in accordance with Example 1, with the difference that instead of aloe vera and panthenol, clotrimazol is added to the mixture. The rest of the procedure is as described in Example 1. The addition of this component destabilizes foam creams to a large extent and typically results in a collapse of the foam cream. One part of the foam cream is subjected to a heat treatment in accordance with Example 2, another part is subjected to a heat treatment in accordance with Example 4.
- The same procedure as described in Example 6 is carried out, with the difference that instead of adding clotrimazol to the foam cream, oak bark extract is added. This additive can destabilize foam creams and typically leads to a collapse of the foam cream.
- The procedure as described in Example 6 is carried out, with the difference that instead of clotrimazol, sage is added to the foam cream. The addition of this component destabilizes foam creams to a large extent and typically leads to a collapse of the foam cream.
- The procedure as described in Example 6 is carried out, with the difference that instead of clotrimazol, rosemary is added to the foam cream. The addition of this component destabilizes foam creams to a large extent and typically leads to a collapse of the foam cream.
- The procedure as described in Example 6 is repeated, with the difference at instead of clotrimazol, arnica is added to the foam cream. The addition of this component destabilizes foam creams to a large extent and typically leads to a collapse of the foam cream.
- The procedure as described in Example 6 is repeated, with the difference that camphor is added to the foam cream instead of clotrimazol. The addition of this component destabilizes foam creams to a large extent and typically leads to a collapse of the foam cream.
- The foam creams in accordance with Examples 2 to 11, which were subjected to a heat treatment are stable. A collapse of these creams could not be observed. The foam creams in accordance with Example 1 without a heat treatment, however, tend to collapse.
Claims (19)
1. A method for the manufacture of a stable foam cream, comprising lipophilic and hydrophilic components and a propellant gas, characterized in that in said method a cream preparation comprising lipophilic and hydrophilic components is prepared,
then, propellant gas is added so that a foam cream is formed and the foam cream is subjected to a heat treatment,
and/or the propellant gas is heated before and/or during the addition to the cream preparation.
2. Method according to claim 1 , characterized in that the heat treatment is carried out at a temperature of at least 20° C.
3. Method according to any one of claims 1 or 2, characterized in that the heat treatment is carried out for a time period of at least 5 minutes.
4. Method according to any one of claims 1 to 3 , characterized in that the foam cream is provided as a two phase system.
5. Method according to any one of claims 1 to 4 , characterized in that the lipophilic components are selected from fatty acids and dimethyl polysiloxanes, and the hydrophilic components are selected from the group consisting of triethanol amine, mono propylene glycol, glycerine, sorbitol, poly(ethylene glycol) and poly(vinyl pyrrolidone)
6. Method according to any one of claims 1 to 5 , characterized in that the foam cream comprises C10- to-C22 fatty acids, emulsifiers and co-emulsifiers.
7. Method according to any one of claims 1 to 6 , characterized in that the foam cream comprises
4 to 15 percent by weight of oil-in-water emulsifier,
1 to 10 percent by weight of fatty acid,
0.4 to 2.3 percent by weight of moisturiser,
0.05 to 1 percent by weight of skin care agent and
water balancing to 100 percent by weight.
8. Method according to any one of claims 1 to 7 , characterized in that the foam creams comprises
1 to 3 percent by weight of glyceryl stearate,
3 to 6 percent by weight cetearyl alcohol,
4 to 6 percent by weight of stearic acid,
0.5 to 2 percent of weight of paraffin,
0.4 to 2.3 percent by weight of triceteareth-4-phosphate,
1.5 to 4 percent by weight propylene glycol,
1.3 to 4.2 percent by weight of glycerine,
1 to 3 percent by weight of cetyl-sarcosinate,
0.05 to 1 percent by weight of allantoin and
water balancing to 100 percent by weight.
9. Method according to any one of claims 1 to 8 , characterized in that the foam cream additionally comprises hydrating (moisture binding) substances like urea, ethoxy diglycol, sodium chloride, magnesium chloride, sorbit, dexpanthenol, sodium lactate and/or additives like clotrimazol, oak bark extract, sage, rosemary, arnica, aloe vera, panthenol and/or camphor.
10. Method according to any one of claims 1 to 9 , characterized in that the foam cream collapses, or partly collapses, after addition of the propellant gas and before conducting the heat treatment.
11. Stable foam cream, obtainable by a method according to any one of claims 1 to 10 .
12. Stable foam cream according to claim 11 , comprising lipophilic and hydrophilic components and a propellant gas, obtainable by subjecting the foam cream to a heat treatment, characterized in that the heat treatment is carried out for a time period of at least 5 minutes and/or for 5 minutes to 20 hours at 30 to 75° C.
13. Stable foam cream according to claims 11 or 12, characterized in that the heat treatment is conducted after addition of the propellant gas.
14. Stable foam cream according to one of claims 11 to 13 , characterized in that the foam cream is a two-phase system.
15. Stable foam cream according to anyone of claims 11 to 14 , characterized in that the lipophilic components are selected from fatty acids and dimethyl polysiloxanes and the hydrophilic components are selected from the group consisting of triethanolamine, mono propylene glycol, glycerine, sorbitol, poly(ethylene glycol) and poly(vinyl pyrrolidone).
16. Stable foam cream according to any one of claims 11 to 15 , characterized in that the foam cream comprises C10- to C22-fatty acids, emulsifiers and co-emulsifiers.
17. Stable foam cream according to any one of claims 11 to 16 , characterized in that the foam cream comprises
4 to 15 percent by weight of oil in water emulsifier,
1 to 10 percent by weight of fatty acid,
0.4 to 2.3 percent by weight moisturiser,
0.05 to 1 percent by weight skin care agent and
water balancing to 100 percent by weight.
18. Stable foam cream according to any one of claims 11 to 17 , characterized in that the foam cream comprises
1 to 3 percent by weight of glyceryl stearate,
3 to 6 percent by weight cetearyl alcohol,
4 to 6 percent by weight of stearic acid,
0.5 to 2 percent of weight of paraffin,
0.4 to 2.3 percent by weight of triceteareth-4-phosphate,
1.5 to 4 percent by weight propylene glycol,
1.3 to 4.2 percent by weight of glycerine,
1 to 3 percent by weight of cetyl-sarcosinate,
0.05 to 1 percent by weight of allantoin, and
water balancing to 100 percent by weight.
19. Stable foam cream according to any one of claims 11 to 18 , characterized in that the foam cream additionally comprises hydrating (moisture binding) substances like urea, ethoxy diglycol, sodium chloride, magnesium chloride, sorbit, dexpanthenol, sodium lactate and/or additives like clotrimazol, oak bark extract, sage, rosemary, arnica, aloe vera, panthenol and/or camphor.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/538,666 US20070134167A2 (en) | 2002-12-12 | 2003-12-12 | Stable foam cream |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43263202P | 2002-12-12 | 2002-12-12 | |
EP02027828.9 | 2002-12-12 | ||
EP02027828 | 2002-12-12 | ||
DEEP02027828.9 | 2002-12-12 | ||
US10/538,666 US20070134167A2 (en) | 2002-12-12 | 2003-12-12 | Stable foam cream |
PCT/EP2003/014153 WO2004052317A1 (en) | 2002-12-12 | 2003-12-12 | Stable foam cream |
Publications (3)
Publication Number | Publication Date |
---|---|
US20060099151A1 true US20060099151A1 (en) | 2006-05-11 |
US20060239937A2 US20060239937A2 (en) | 2006-10-26 |
US20070134167A2 US20070134167A2 (en) | 2007-06-14 |
Family
ID=35912802
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/538,666 Abandoned US20070134167A2 (en) | 2002-12-12 | 2003-12-12 | Stable foam cream |
Country Status (7)
Country | Link |
---|---|
US (1) | US20070134167A2 (en) |
EP (1) | EP1569598A1 (en) |
JP (1) | JP2006510651A (en) |
CN (1) | CN1723009A (en) |
AU (1) | AU2003293865A1 (en) |
EA (1) | EA009660B1 (en) |
WO (1) | WO2004052317A1 (en) |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070098647A1 (en) * | 2005-09-28 | 2007-05-03 | Neubourg Skin Care Gmbh & Co. Kg | Skin care products |
US20110230449A1 (en) * | 2007-08-02 | 2011-09-22 | Clariant Finance (Bvi) Limited | Alkoxylated Phosphoric Acid Triesters With A High Degree Of Alkoxylation |
US8343945B2 (en) | 2007-12-07 | 2013-01-01 | Foamix Ltd. | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof |
US8362091B2 (en) | 2003-08-04 | 2013-01-29 | Foamix Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
US8435498B2 (en) | 2002-10-25 | 2013-05-07 | Foamix Ltd. | Penetrating pharmaceutical foam |
US8486376B2 (en) | 2002-10-25 | 2013-07-16 | Foamix Ltd. | Moisturizing foam containing lanolin |
US8486374B2 (en) | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
US8486375B2 (en) | 2003-04-28 | 2013-07-16 | Foamix Ltd. | Foamable compositions |
US8512718B2 (en) | 2000-07-03 | 2013-08-20 | Foamix Ltd. | Pharmaceutical composition for topical application |
US8518378B2 (en) | 2003-08-04 | 2013-08-27 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US8518376B2 (en) | 2007-12-07 | 2013-08-27 | Foamix Ltd. | Oil-based foamable carriers and formulations |
US8618081B2 (en) | 2009-10-02 | 2013-12-31 | Foamix Ltd. | Compositions, gels and foams with rheology modulators and uses thereof |
US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
US8709385B2 (en) | 2008-01-14 | 2014-04-29 | Foamix Ltd. | Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses |
US8722021B2 (en) | 2002-10-25 | 2014-05-13 | Foamix Ltd. | Foamable carriers |
US8795635B2 (en) | 2006-11-14 | 2014-08-05 | Foamix Ltd. | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
US8900554B2 (en) | 2002-10-25 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Foamable composition and uses thereof |
US9072667B2 (en) | 2009-07-29 | 2015-07-07 | Foamix Pharmaceuticals Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
US9167813B2 (en) | 2009-07-29 | 2015-10-27 | Foamix Pharmaceuticals Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US9320705B2 (en) | 2002-10-25 | 2016-04-26 | Foamix Pharmaceuticals Ltd. | Sensation modifying topical composition foam |
US9439857B2 (en) | 2007-11-30 | 2016-09-13 | Foamix Pharmaceuticals Ltd. | Foam containing benzoyl peroxide |
US9539208B2 (en) | 2002-10-25 | 2017-01-10 | Foamix Pharmaceuticals Ltd. | Foam prepared from nanoemulsions and uses |
US9622947B2 (en) | 2002-10-25 | 2017-04-18 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
US9884017B2 (en) | 2009-04-28 | 2018-02-06 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
US10398641B2 (en) | 2016-09-08 | 2019-09-03 | Foamix Pharmaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8119150B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Non-flammable insecticide composition and uses thereof |
US8119109B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Foamable compositions, kits and methods for hyperhidrosis |
DE202004021449U1 (en) * | 2004-10-21 | 2008-02-28 | Neubourg Skin Care Gmbh & Co. Kg | Use of urea for the treatment of age spots |
EP2145012A2 (en) * | 2007-04-04 | 2010-01-20 | F. Hoffmann-Roche AG | Microbial reduction of an acetoxyketone |
US20090036856A1 (en) * | 2007-07-31 | 2009-02-05 | Kimberly-Clark Worldwide, Inc. | Triggerable self-generating liquid foam barrier/interceptor |
US8174881B2 (en) | 2009-11-24 | 2012-05-08 | Micron Technology, Inc. | Techniques for reducing disturbance in a semiconductor device |
BR112013027773A2 (en) * | 2011-05-12 | 2016-08-23 | Unilever Nv | skin whitening makeup |
DE102015221568A1 (en) * | 2015-11-04 | 2017-05-04 | Beiersdorf Ag | Cosmetic foam of an emulsion containing glycerol and alcohol |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3970584A (en) * | 1973-02-14 | 1976-07-20 | S. C. Johnson & Son, Inc. | Aerosol package containing a foam-forming emulsion and propellent system |
US6423323B2 (en) * | 1997-08-18 | 2002-07-23 | Stephanie Neubourg | Foam skin cream, uses of the foam skin protection cream and a process for its preparation |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4753747A (en) * | 1987-05-12 | 1988-06-28 | Colgate-Palmolive Co. | Process of neutralizing mono-carboxylic acid |
SE520811C2 (en) * | 1997-01-17 | 2003-08-26 | Ponsus Ab | Skin protection preparations containing lipophilic and hydrophilic components, method of preparation and use thereof |
-
2003
- 2003-12-12 US US10/538,666 patent/US20070134167A2/en not_active Abandoned
- 2003-12-12 EP EP03789251A patent/EP1569598A1/en not_active Withdrawn
- 2003-12-12 CN CNA2003801054579A patent/CN1723009A/en active Pending
- 2003-12-12 JP JP2004558079A patent/JP2006510651A/en active Pending
- 2003-12-12 WO PCT/EP2003/014153 patent/WO2004052317A1/en not_active Application Discontinuation
- 2003-12-12 AU AU2003293865A patent/AU2003293865A1/en not_active Abandoned
- 2003-12-12 EA EA200500920A patent/EA009660B1/en not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3970584A (en) * | 1973-02-14 | 1976-07-20 | S. C. Johnson & Son, Inc. | Aerosol package containing a foam-forming emulsion and propellent system |
US6423323B2 (en) * | 1997-08-18 | 2002-07-23 | Stephanie Neubourg | Foam skin cream, uses of the foam skin protection cream and a process for its preparation |
Cited By (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8512718B2 (en) | 2000-07-03 | 2013-08-20 | Foamix Ltd. | Pharmaceutical composition for topical application |
US11033491B2 (en) | 2002-10-25 | 2021-06-15 | Vyne Therapeutics Inc. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US8840869B2 (en) | 2002-10-25 | 2014-09-23 | Foamix Ltd. | Body cavity foams |
US10322085B2 (en) | 2002-10-25 | 2019-06-18 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US8435498B2 (en) | 2002-10-25 | 2013-05-07 | Foamix Ltd. | Penetrating pharmaceutical foam |
US8486376B2 (en) | 2002-10-25 | 2013-07-16 | Foamix Ltd. | Moisturizing foam containing lanolin |
US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US10117812B2 (en) | 2002-10-25 | 2018-11-06 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
US9539208B2 (en) | 2002-10-25 | 2017-01-10 | Foamix Pharmaceuticals Ltd. | Foam prepared from nanoemulsions and uses |
US9320705B2 (en) | 2002-10-25 | 2016-04-26 | Foamix Pharmaceuticals Ltd. | Sensation modifying topical composition foam |
US9492412B2 (en) | 2002-10-25 | 2016-11-15 | Foamix Pharmaceuticals Ltd. | Penetrating pharmaceutical foam |
US9622947B2 (en) | 2002-10-25 | 2017-04-18 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
US10821077B2 (en) | 2002-10-25 | 2020-11-03 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
US9713643B2 (en) | 2002-10-25 | 2017-07-25 | Foamix Pharmaceuticals Ltd. | Foamable carriers |
US8722021B2 (en) | 2002-10-25 | 2014-05-13 | Foamix Ltd. | Foamable carriers |
US8741265B2 (en) | 2002-10-25 | 2014-06-03 | Foamix Ltd. | Penetrating pharmaceutical foam |
US8900554B2 (en) | 2002-10-25 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Foamable composition and uses thereof |
US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
US8486375B2 (en) | 2003-04-28 | 2013-07-16 | Foamix Ltd. | Foamable compositions |
US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
US9636405B2 (en) | 2003-08-04 | 2017-05-02 | Foamix Pharmaceuticals Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
US8362091B2 (en) | 2003-08-04 | 2013-01-29 | Foamix Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
US8486374B2 (en) | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
US8518378B2 (en) | 2003-08-04 | 2013-08-27 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US8703105B2 (en) | 2003-08-04 | 2014-04-22 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US9050253B2 (en) | 2003-08-04 | 2015-06-09 | Foamix Pharmaceuticals Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US9101662B2 (en) | 2003-08-04 | 2015-08-11 | Foamix Pharmaceuticals Ltd. | Compositions with modulating agents |
US20070098647A1 (en) * | 2005-09-28 | 2007-05-03 | Neubourg Skin Care Gmbh & Co. Kg | Skin care products |
US9682021B2 (en) | 2006-11-14 | 2017-06-20 | Foamix Pharmaceuticals Ltd. | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
US8795635B2 (en) | 2006-11-14 | 2014-08-05 | Foamix Ltd. | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
US20110230449A1 (en) * | 2007-08-02 | 2011-09-22 | Clariant Finance (Bvi) Limited | Alkoxylated Phosphoric Acid Triesters With A High Degree Of Alkoxylation |
US9662298B2 (en) | 2007-08-07 | 2017-05-30 | Foamix Pharmaceuticals Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
US10369102B2 (en) | 2007-08-07 | 2019-08-06 | Foamix Pharmaceuticals Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
US11103454B2 (en) | 2007-08-07 | 2021-08-31 | Vyne Therapeutics Inc. | Wax foamable vehicle and pharmaceutical compositions thereof |
US9439857B2 (en) | 2007-11-30 | 2016-09-13 | Foamix Pharmaceuticals Ltd. | Foam containing benzoyl peroxide |
US9549898B2 (en) | 2007-12-07 | 2017-01-24 | Foamix Pharmaceuticals Ltd. | Oil and liquid silicone foamable carriers and formulations |
US9795564B2 (en) | 2007-12-07 | 2017-10-24 | Foamix Pharmaceuticals Ltd. | Oil-based foamable carriers and formulations |
US8518376B2 (en) | 2007-12-07 | 2013-08-27 | Foamix Ltd. | Oil-based foamable carriers and formulations |
US9161916B2 (en) | 2007-12-07 | 2015-10-20 | Foamix Pharmaceuticals Ltd. | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof |
US8900553B2 (en) | 2007-12-07 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Oil and liquid silicone foamable carriers and formulations |
US11433025B2 (en) | 2007-12-07 | 2022-09-06 | Vyne Therapeutics Inc. | Oil foamable carriers and formulations |
US8343945B2 (en) | 2007-12-07 | 2013-01-01 | Foamix Ltd. | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof |
US8709385B2 (en) | 2008-01-14 | 2014-04-29 | Foamix Ltd. | Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses |
US10213384B2 (en) | 2009-04-28 | 2019-02-26 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
US9884017B2 (en) | 2009-04-28 | 2018-02-06 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
US10588858B2 (en) | 2009-04-28 | 2020-03-17 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
US10363216B2 (en) | 2009-04-28 | 2019-07-30 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
US11219631B2 (en) | 2009-07-29 | 2022-01-11 | Vyne Pharmaceuticals Inc. | Foamable compositions, breakable foams and their uses |
US9072667B2 (en) | 2009-07-29 | 2015-07-07 | Foamix Pharmaceuticals Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
US9167813B2 (en) | 2009-07-29 | 2015-10-27 | Foamix Pharmaceuticals Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
US10092588B2 (en) | 2009-07-29 | 2018-10-09 | Foamix Pharmaceuticals Ltd. | Foamable compositions, breakable foams and their uses |
US10350166B2 (en) | 2009-07-29 | 2019-07-16 | Foamix Pharmaceuticals Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
US9572775B2 (en) | 2009-07-29 | 2017-02-21 | Foamix Pharmaceuticals Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
US10322186B2 (en) | 2009-10-02 | 2019-06-18 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US10029013B2 (en) | 2009-10-02 | 2018-07-24 | Foamix Pharmaceuticals Ltd. | Surfactant-free, water-free formable composition and breakable foams and their uses |
US10265404B2 (en) | 2009-10-02 | 2019-04-23 | Foamix Pharmaceuticals Ltd. | Compositions, gels and foams with rheology modulators and uses thereof |
US10213512B2 (en) | 2009-10-02 | 2019-02-26 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US8865139B1 (en) | 2009-10-02 | 2014-10-21 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US10137200B2 (en) | 2009-10-02 | 2018-11-27 | Foamix Pharmaceuticals Ltd. | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
US8871184B2 (en) | 2009-10-02 | 2014-10-28 | Foamix Ltd. | Topical tetracycline compositions |
US10086080B2 (en) | 2009-10-02 | 2018-10-02 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US8992896B2 (en) | 2009-10-02 | 2015-03-31 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US10463742B2 (en) | 2009-10-02 | 2019-11-05 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US10517882B2 (en) | 2009-10-02 | 2019-12-31 | Foamix Pharmaceuticals Ltd. | Method for healing of an infected acne lesion without scarring |
US10238746B2 (en) | 2009-10-02 | 2019-03-26 | Foamix Pharmaceuticals Ltd | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
US10610599B2 (en) | 2009-10-02 | 2020-04-07 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US10821187B2 (en) | 2009-10-02 | 2020-11-03 | Foamix Pharmaceuticals Ltd. | Compositions, gels and foams with rheology modulators and uses thereof |
US8618081B2 (en) | 2009-10-02 | 2013-12-31 | Foamix Ltd. | Compositions, gels and foams with rheology modulators and uses thereof |
US10835613B2 (en) | 2009-10-02 | 2020-11-17 | Foamix Pharmaceuticals Ltd. | Compositions, gels and foams with rheology modulators and uses thereof |
US9675700B2 (en) | 2009-10-02 | 2017-06-13 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US10967063B2 (en) | 2009-10-02 | 2021-04-06 | Vyne Therapeutics Inc. | Surfactant-free, water-free formable composition and breakable foams and their uses |
US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
US8945516B2 (en) | 2009-10-02 | 2015-02-03 | Foamix Pharmaceuticals Ltd. | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
US10849847B2 (en) | 2016-09-08 | 2020-12-01 | Foamix Pharamaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
US11324691B2 (en) | 2016-09-08 | 2022-05-10 | Journey Medical Corporation | Compositions and methods for treating rosacea and acne |
US10398641B2 (en) | 2016-09-08 | 2019-09-03 | Foamix Pharmaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
Also Published As
Publication number | Publication date |
---|---|
CN1723009A (en) | 2006-01-18 |
AU2003293865A1 (en) | 2004-06-30 |
EA009660B1 (en) | 2008-02-28 |
US20070134167A2 (en) | 2007-06-14 |
JP2006510651A (en) | 2006-03-30 |
WO2004052317A1 (en) | 2004-06-24 |
US20060239937A2 (en) | 2006-10-26 |
EP1569598A1 (en) | 2005-09-07 |
EA200500920A1 (en) | 2006-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060099151A1 (en) | Stable foam cream | |
AU766944B2 (en) | Aerosol ointment compositions and method of manufacture | |
US3970584A (en) | Aerosol package containing a foam-forming emulsion and propellent system | |
US5902778A (en) | Post foaming gel shaving composition | |
EP0691840B1 (en) | Silicone based skin care products | |
WO2014027410A1 (en) | Foam-forming aerosol product | |
JPH02229539A (en) | Improved silicone surfactant | |
JPS63183520A (en) | Emulsion type hair cosmetic | |
DE69415677T2 (en) | SHAVERS | |
US20140079648A1 (en) | Antimicrobial alcoholic foamable compositions | |
EP1575542A1 (en) | Aerosol delivery systems | |
EP1718404B1 (en) | Polyaphron dispersions containing a complex internal phase | |
KR101741981B1 (en) | Aerosol cosmetic composition of leave on type | |
JP4707278B2 (en) | Discharge product | |
CN102149365B (en) | Self-heating shaving compositions | |
US3728276A (en) | Pressurized foam-producing composition and process therefor | |
JP2001247431A (en) | Aerosol composition and aerosol product for depilation | |
JPS58189106A (en) | Spray composition | |
JPH0559890B2 (en) | ||
JP3679252B2 (en) | Aerosol composition | |
US5000938A (en) | Protective aerated foam hand lotion and process for preparing the same | |
EP3043871A1 (en) | Aerosol container comprising a dermatological composition and a foaming agent | |
JP2708691B2 (en) | Aerosol composition containing powder | |
WO2020192576A1 (en) | Mousse products, methods and devices | |
JPH0457642B2 (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: NEUBOURG SKIN CARE GMBH & CO. KG, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NEUBOURG, FRITZ;REEL/FRAME:016452/0156 Effective date: 20050801 |
|
AS | Assignment |
Owner name: NEUBOURG SKIN CARE GMBH & CO. KG, GERMANY Free format text: CHANGE OF ADDRESS;ASSIGNOR:NEUBOURG SKIN CARE GMBH & CO. KG;REEL/FRAME:018980/0711 Effective date: 20061128 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |